BRIEF published on 03/17/2026 at 07:08, 7 months 14 days ago Sartorius Stedim Biotech refines its strategy and aims for ambitious growth EBITDA Sartorius Stedim Biotech Product Portfolio Growth Objectives Biopharmaceutical Strategy
BRIEF published on 03/17/2026 at 07:08, 7 months 14 days ago Sartorius Stedim Biotech Sets New Growth Targets with Biopharma Focus Advanced Therapies Market Expansion Growth Targets Biopharma Strategy Bioprocessing Technologies
PRESS RELEASE published on 03/17/2026 at 07:03, 7 months 14 days ago Sartorius Stedim Biotech sharpens strategy with biopharma focus and sets new mid-term growth targets Sartorius Stedim Biotech sharpens focus on biopharma with new growth targets and strategic initiatives to drive above-market growth and margin expansion Sartorius Stedim Biotech Strategic Initiatives Growth Targets Biopharma Above-market Growth
BRIEF published on 03/02/2026 at 16:30, 7 months 29 days ago Sartorius Stedim Biotech: Statement on Share Capital Share Capital Voting Rights Actions Sartorius Stedim Biotech AMF Regulations
BRIEF published on 03/02/2026 at 16:30, 7 months 29 days ago Sartorius Stedim Biotech: Share Capital and Voting Rights Update Share Capital Voting Rights French Commercial Code Sartorius Stedim Biotech EQS News Service
PRESS RELEASE published on 03/02/2026 at 16:25, 7 months 29 days ago Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL Sartorius Stedim Biotech SA declares number of shares and voting rights in issued capital as of February 28, 2026 Voting Rights Capital Déclaration Shares Sartorius Stedim Biotech
PRESS RELEASE published on 02/16/2026 at 09:13, 8 months 12 days ago Sartorius Stedim Biotech releases Universal Registration Document 2025 Sartorius Stedim Biotech releases Universal Registration Document 2025, providing insights into its financial performance and strategic outlook for the future Financial Report Sartorius Stedim Biotech Annual Results Universal Registration Document Biopharma Industry
BRIEF published on 02/16/2026 at 09:13, 8 months 12 days ago Sartorius Stedim Biotech Releases 2025 Universal Registration Document Global Operations Sartorius Stedim Biotech Universal Registration Document Biopharmaceutical Solutions 2025 Financials
BRIEF published on 02/16/2026 at 09:13, 8 months 12 days ago Sartorius Stedim Biotech publishes its 2025 Universal Registration Document Consolidated Financial Statements Sartorius Stedim Biotech Universal Registration Document Fiscal Year 2025 2026 Objectives
PRESS RELEASE published on 02/16/2026 at 09:09, 8 months 12 days ago Sartorius Stedim Biotech SA: Information on Document Availability Sartorius Stedim Biotech releases Universal Registration Document 2025 with business development and financial statements. Leading biopharmaceutical partner based in Aubagne, France Financial Statements Business Development Sartorius Stedim Biotech Biopharmaceutical Industry Universal Registration Document
Published on 10/30/2026 at 23:35, 1 day ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 5 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 8 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/31/2026 at 16:35, 7 hours 54 minutes ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 1 hour ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 1 day 5 hours ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 1 day 1 hour ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 1 day 12 hours ago Capital increase through exercise of subscription rights
